Alx Retained Earnings from 2010 to 2024

ALXO Stock  USD 16.86  0.01  0.06%   
Alx Oncology Retained Earnings yearly trend continues to be very stable with very little volatility. Retained Earnings are likely to grow to about -462 M this year. Retained Earnings is the cumulative amount of net income that Alx Oncology Holdings retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2010-12-31
Previous Quarter
-486.3 M
Current Value
-462 M
Quarterly Volatility
154.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Alx Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alx main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9.5 M or Depreciation And Amortization of 877.8 K, as well as many exotic indicators such as Price To Sales Ratio of 2.7 K, Dividend Yield of 0.0 or PTB Ratio of 3.54. Alx financial statements analysis is a perfect complement when working with Alx Oncology Valuation or Volatility modules.
  
This module can also supplement Alx Oncology's financial leverage analysis and stock options assessment as well as various Alx Oncology Technical models . Check out the analysis of Alx Oncology Correlation against competitors.

Latest Alx Oncology's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Alx Oncology Holdings over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Alx Oncology's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alx Oncology's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (486.27 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Alx Retained Earnings Regression Statistics

Arithmetic Mean(143,255,827)
Coefficient Of Variation(107.80)
Mean Deviation120,354,546
Median(53,539,000)
Standard Deviation154,434,858
Sample Variance23850.1T
Range432.7M
R-Value(0.79)
Mean Square Error9639.9T
R-Squared0.62
Significance0.0005
Slope(27,293,546)
Total Sum of Squares333901.8T

Alx Retained Earnings History

2024-462 M
2023-486.3 M
2022-325.5 M
2021-202 M
2020-118.5 M
2019-72.8 M

Other Fundumenentals of Alx Oncology Holdings

Alx Oncology Retained Earnings component correlations

-0.380.99-0.85-0.650.510.450.940.681.01.0-0.960.990.940.380.960.92-0.32-0.320.42
-0.38-0.310.74-0.19-0.080.01-0.27-0.18-0.39-0.410.22-0.42-0.220.26-0.24-0.21-0.61-0.610.4
0.99-0.31-0.81-0.690.560.520.970.660.990.98-0.970.970.970.410.970.96-0.35-0.350.5
-0.850.74-0.810.18-0.17-0.27-0.7-0.69-0.86-0.880.69-0.9-0.670.09-0.7-0.66-0.19-0.190.07
-0.65-0.19-0.690.18-0.87-0.46-0.8-0.16-0.63-0.590.83-0.54-0.83-0.93-0.83-0.820.810.81-0.93
0.51-0.080.56-0.17-0.870.240.74-0.060.50.44-0.670.390.740.850.710.74-0.49-0.490.83
0.450.010.52-0.27-0.460.240.550.210.460.42-0.560.40.550.390.520.56-0.26-0.260.48
0.94-0.270.97-0.7-0.80.740.550.510.940.91-0.970.881.00.580.991.0-0.41-0.410.66
0.68-0.180.66-0.69-0.16-0.060.210.510.680.71-0.530.730.51-0.090.540.51-0.08-0.080.06
1.0-0.390.99-0.86-0.630.50.460.940.681.0-0.950.990.930.360.950.92-0.31-0.310.41
1.0-0.410.98-0.88-0.590.440.420.910.711.0-0.931.00.910.310.930.89-0.29-0.290.35
-0.960.22-0.970.690.83-0.67-0.56-0.97-0.53-0.95-0.93-0.91-0.98-0.62-0.99-0.970.520.52-0.64
0.99-0.420.97-0.9-0.540.390.40.880.730.991.0-0.910.880.250.910.86-0.26-0.260.29
0.94-0.220.97-0.67-0.830.740.551.00.510.930.91-0.980.880.610.991.0-0.46-0.460.69
0.380.260.410.09-0.930.850.390.58-0.090.360.31-0.620.250.610.60.6-0.8-0.80.92
0.96-0.240.97-0.7-0.830.710.520.990.540.950.93-0.990.910.990.60.98-0.49-0.490.65
0.92-0.210.96-0.66-0.820.740.561.00.510.920.89-0.970.861.00.60.98-0.43-0.430.7
-0.32-0.61-0.35-0.190.81-0.49-0.26-0.41-0.08-0.31-0.290.52-0.26-0.46-0.8-0.49-0.431.0-0.77
-0.32-0.61-0.35-0.190.81-0.49-0.26-0.41-0.08-0.31-0.290.52-0.26-0.46-0.8-0.49-0.431.0-0.77
0.420.40.50.07-0.930.830.480.660.060.410.35-0.640.290.690.920.650.7-0.77-0.77
Click cells to compare fundamentals

About Alx Oncology Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Alx Oncology income statement, its balance sheet, and the statement of cash flows. Alx Oncology investors use historical funamental indicators, such as Alx Oncology's Retained Earnings, to determine how well the company is positioned to perform in the future. Although Alx Oncology investors may use each financial statement separately, they are all related. The changes in Alx Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alx Oncology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Alx Oncology Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Alx Oncology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Retained Earnings-486.3 M-462 M
Retained Earnings Total Equity-292.9 M-307.6 M

Pair Trading with Alx Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alx Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving against Alx Stock

  0.61BHC Bausch Health Companies Financial Report 2nd of May 2024 PairCorr
  0.61BMY Bristol Myers SquibbPairCorr
  0.58DRRX Durect Earnings Call This WeekPairCorr
  0.55FLGC Flora Growth Corp Financial Report 20th of May 2024 PairCorr
  0.42HCM HUTCHMED DRCPairCorr
The ability to find closely correlated positions to Alx Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alx Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alx Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alx Oncology Holdings to buy it.
The correlation of Alx Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alx Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alx Oncology Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alx Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock:
Check out the analysis of Alx Oncology Correlation against competitors.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Alx Stock analysis

When running Alx Oncology's price analysis, check to measure Alx Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alx Oncology is operating at the current time. Most of Alx Oncology's value examination focuses on studying past and present price action to predict the probability of Alx Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alx Oncology's price. Additionally, you may evaluate how the addition of Alx Oncology to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
FinTech Suite
Use AI to screen and filter profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Is Alx Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.74)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.39)
Return On Equity
(0.71)
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.